(Total Views: 327)
Posted On: 01/04/2018 9:14:57 PM
Post# of 72436
I get the feeling from some posters that serious talks with BP will begin only after P2 data is released. IMO talks started once they signed the CDA and they and mgt have been feeling each other out and communicating heavily and continuously behind the scene as to the science of each drug. Thus, the release of P2 data is the heralding of the last hurrah before a deal, not the opening act. If I am a BP and I know IPIX has other CDA's, I am not going to have sketchy communications with them, I am going to have some one/team talking to them constantly to let IPIX know how serious is my intention to be their primary partner.
Just a gut feeling, but I believe mgt already knows who they want to partner with and who they are going to sign as to partnerships and it isn't going to take that long once final (or possibly even top line for P if it is real strong data) results are published. Certainly not months after results.
I was shocked at the speed of the secondary endpoint data PR for B-OM as I had that expectation schedule for the end of Jan time frame at best and most likely mid-Feb. Then I heard from another board that the CSR (?) final report to FDA to get going on a P3 is possibly going to ready before the end of the month? Way faster than I expected. That just leaves the P top line data which I have been thinking is most likely by mid-March but now I believe that may come a bit quicker than I had thought so anything after mid-Feb wouldn't surprise me.
I knew we had the products, I am amazed at how quickly we are knocking out the requirements for the continuation of the trials. Pretty sure that is due to Dr. B. Worth every penny we are paying him IMO.
Just a gut feeling, but I believe mgt already knows who they want to partner with and who they are going to sign as to partnerships and it isn't going to take that long once final (or possibly even top line for P if it is real strong data) results are published. Certainly not months after results.
I was shocked at the speed of the secondary endpoint data PR for B-OM as I had that expectation schedule for the end of Jan time frame at best and most likely mid-Feb. Then I heard from another board that the CSR (?) final report to FDA to get going on a P3 is possibly going to ready before the end of the month? Way faster than I expected. That just leaves the P top line data which I have been thinking is most likely by mid-March but now I believe that may come a bit quicker than I had thought so anything after mid-Feb wouldn't surprise me.
I knew we had the products, I am amazed at how quickly we are knocking out the requirements for the continuation of the trials. Pretty sure that is due to Dr. B. Worth every penny we are paying him IMO.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)